Causal Machine Learning for Biomarker Subgroup Discovery in Randomised Trials
Decreasing costs of high-throughput ‘omics, as well as new technologies such as the Olink proteomics platform, has driven wider application in clinical trials, for example to inform precision medicine
lshtm.ac.uk